Innovent delivers oral presentation of updated results from a pivotal phase 2 study of Dupert (fulzerasib) in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation
- Innovent presented updated results from a pivotal Phase 2 clinical trial of Dupert (fulzerasib) at the 2024 World Conference on Lung Cancer.
- The study involved 116 NSCLC patients with KRAS G12C mutation, showing a confirmed objective response rate (ORR) of 49.1% and a disease control rate (DCR) of 90.5%.
- Median progression-free survival (PFS) was 9.7 months, with median overall survival (OS) not yet reached.
- Dupert was well-tolerated, with most treatment-related adverse events being Grade 1-2.
Read more
Datopotamab deruxtecan shows promising results in advanced nonsquamous non-small cell lung cancer
- TROPION-Lung01 phase 3 trial results show datopotamab deruxtecan (Dato-DXd) improved median overall survival (OS) to 14.6 months in patients with advanced nonsquamous NSCLC.
- Compared to docetaxel, Dato-DXd showed a 2.3-month improvement in OS for nonsquamous NSCLC patients (14.6 months vs. 12.3 months).
- The safety profile of Dato-DXd was consistent with previous analyses, showing lower rates of dose reduction and discontinuation due to adverse events compared to docetaxel.
- The OS data have been shared with health authorities currently reviewing applications for this indication.
Read more
ImmunityBio presents positive long-term overall survival data in non-small cell lung cancer patients
- ImmunityBio announced positive results from its QUILT 3.055 trial, showing long-term survival of up to five years for advanced NSCLC patients treated with checkpoint inhibitors.
- The phase 2b study of ANKTIVA in combination with KEYTRUDA or OPDIVO showed overall survival rates of 57% at 12 months and 34% at 18 months.
- The QUILT-3.055 study enrolled 86 patients with 2nd and 3rd line+ NSCLC who had failed prior CPI therapies.
- Based on these results, ImmunityBio is initiating Phase 3 trials of ANKTIVA plus KEYTRUDA or OPDIVO in 1st and 2nd line NSCLC.
Read more
Datopotamab deruxtecan shows promising results in TROPION-Lung01 Phase III trial
- TROPION-Lung01 Phase III trial results show datopotamab deruxtecan (Dato-DXd) improved median overall survival (OS) to 14.6 months in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
- Compared to docetaxel, Dato-DXd showed a 2.3-month improvement in OS for nonsquamous NSCLC patients (14.6 vs. 12.3 months).
- The safety profile of Dato-DXd was consistent with previous analyses, showing lower rates of dose reduction and discontinuation due to adverse events compared to docetaxel.
- The OS data have been shared with health authorities currently reviewing applications for this indication.
Read more
OSE Immunotherapeutics launches global phase 3 study for cancer vaccine Tedopi in second-line NSCLC
- OSE Immunotherapeutics has initiated the global Phase 3 'Artemia' trial for Tedopi in second-line treatment of metastatic non-small cell lung cancer (NSCLC).
- The trial is being conducted in the US, Canada, Europe, and the UK, with regulatory authorizations from 14 countries.
- Artemia is an open-label, randomized trial comparing Tedopi monotherapy to standard care in HLA-A2 positive patients with secondary resistance to immune checkpoint inhibitors.
- The primary endpoint is overall survival, and the trial aims to enroll 363 patients to support regulatory registration in Europe and North America.
Read more
Oryzon announces first patient dosed in phase Ib study of iadademstat in first-line acute myeloid leukemia
- First patient dosed in an investigator-initiated Phase Ib trial of iadademstat in combination with venetoclax and azacitidine for newly diagnosed AML.
- Study aims to test the safety, tolerability, and best dose of the triple combination.
- Trial sponsored by Oregon Health & Science University (OHSU) Knight Cancer Institute.
- Iadademstat is also being evaluated in a company-sponsored Phase Ib trial in combination with gilteritinib for relapsed/refractory AML with FLT3 mutations.
Read more
New results from the investigational agent BAY 2927088 in HER2-mutant non-small cell lung cancer (NSCLC) presented at WCLC
- Bayer presented encouraging results from the Phase I/II SOHO-01 study at the IASLC 2024 World Conference on Lung Cancer.
- The study evaluated the safety and preliminary efficacy of BAY 2927088 in advanced HER2-mutant NSCLC.
- Confirmed objective response rate (ORR) was 72.1%, with a median duration of response (DoR) of 8.7 months.
- The safety profile was manageable, with diarrhea being the most common treatment-related adverse event (TRAEs).
Read more
ONWARD Medical reports half year 2024 results and provides a business update
- Published Up-LIFT Study results in Nature Medicine.
- Submitted De Novo application to FDA for ARC-EX System clearance in the US.
- Secured up to EUR 52.5M in growth financing from Runway Growth Capital.
- Achieved several milestones with ARC-BCI System, including FDA Breakthrough Device Designation and admittance into FDA’s TAP program.
Read more
Vir Biotechnology closes exclusive worldwide license agreement with Sanofi for T-cell engagers
- Vir Biotechnology has closed an exclusive worldwide license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs).
- The agreement includes the use of the PRO-XTEN masking platform for oncology and infectious disease applications.
- Key employees from Sanofi with expertise in TCEs and the PRO-XTEN platform will join Vir.
- Details on the TCEs and development plans will be shared at Vir’s R&D Day in November.
Read more
Botensilimab/balstilimab clinical activity in refractory sarcomas to be presented in oral session at ESMO 2024
- Agenus Inc. will present updated data from the Phase 1 trial of botensilimab and balstilimab in refractory sarcomas at ESMO 2024.
- The presentation will feature efficacy and safety data, focusing on visceral angiosarcoma and leiomyosarcoma.
- Botensilimab is an investigational Fc-enhanced CTLA-4 inhibitor, and balstilimab is an investigational PD-1 antibody.
- The presentation is scheduled for September 13, 2024, from 4:00 p.m. to 5:30 p.m. CEST.
Read more
